

Date 17/04/2025  
Your Ref  
Our Ref 9891

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – CANCER

I write in response to your request for information in relation to cancer prescribing.

Question:

1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

Answer:

Unknown at the level of stage.

Question:

2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:
  - a) Paclitaxel in combination with a platinum-based compound
  - b) Platinum-based therapy alone (cisplatin or carboplatin)
  - c) Bevacizumab in combination with paclitaxel and carboplatin
  - d) Olaparib
  - e) Olaparib + Bevacizumab
  - f) Niraparib
  - g) Rucaparib

Answer:

For 'Ca Ovary Epithelial' disease tree arm

a.	29
b.	26
c.	5<
d.	19
e.	5<
f.	16
g.	0

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common name of Lothian Health Board*

## Question:

3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part

## Answer:

Full Title	Recruited
ATARI: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss	8*
ModiFY: A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer*	5<**
ACTOv: A multicentre phase II randomised controlled trial to evaluate the efficacy of Adaptive Therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high grade serous or high grade endometrioid ovarian cancer	5<
RAMP301: A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)	5<
A Phase Ib, Open-Label Trial of MOv18 IgE in Patients with Advanced Ovarian Cancer	0
SPPRANO: Stereotactic radiotherapy alone or followed by niraparib for oligometastases or oligoprogression in ovarian cancer following PARP inhibitor therapy	0

\* 6 ovarian cancer patients recruited in NHS Lothian

\*\* 5< ovarian cancer patient recruited in NHS Lothian

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

## Question:

4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:
- Olaparib
  - Olaparib + Bevacizumab
  - Niraparib
  - Other treatments

## Answer:

This data is not available.



I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhslothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive